
Curriculum Vitae

Rodolfo P. Sotolongo, M.D., FACC, FSCAI

Present Position:
Interventional Cardiologist
President

Southeast Texas Cardiology Associates II, L.L.P.

2693 North Street
Beaumont, TX 77702
(409) 832-8862 (409) 832-1664 Fax
www.setxcardiology.com

Southeast Texas Clinical Research Center

Founder and Medical Director
2680 McFaddin Avenue
Beaumont, Texas 77702
(409) 839-4003 (409) 839-8469 fax

License#G4209

EDUCATION

09/07/82 - 10/29/82	Baylor College of Medicine Saint Luke's Episcopal Hospital - Houston, TX Advanced Cardiac Fellowship Cardiac Catheterization/Coronary Angioplasty
1978 - 1980	Georgetown University Medical Center Cardiology Fellowship
1977 - 1978	Georgetown University Medicine Division D.C. General Hospital Senior Assistant Resident Medicine
1976 - 1977	Georgetown University Medicine Division D.C. General Hospital Junior Assistant Resident Medicine
1975 - 1976	Georgetown University Medicine Division D.C. General Hospital Straight Medical Internship
1970 - 1975	University of Santiago, Spain Doctor of Medicine

Curriculum Vitae

PROFESSIONAL AND TEACHING EXPERIENCE

Present	Southeast Texas Cardiology Associates, L.L.P. Consultative Cardiology, Interventional Cardiology, Critical Care
1985	Assisted in initiation of coronary Angioplasty Program University of Texas medical Branch - Galveston, Texas John Sealy Hospital
1982 - 2002	Assistant Professor of Medicine teaching Cardiology, CCU, ICU Rotations to UTMB family practice residents
1982 – 2002	Clinical Assistant Professor of Medicine - Cardiology University of Texas Medical Branch - Galveston, Texas
1982 - 1987	Director Medical Intensive Care Unit Mid-Jefferson County Hospital
1980 - 1982	Clinical Instructor of Medicine, University of Miami Department of Medicine-Cardiology
1980 - 1982	Staff Physician, Miami Heart Institute Miami Beach, Florida
1979 - 1980	Instructor of Medicine, Georgetown University Medical Center Department of Medicine

BOARD CERTIFICATION

1999	Diplomate American Board of Cardiovascular Disease: Interventional Cardiology
1997	Recertified Critical Care Medicine
1987	Board Certified Critical Care Medicine
1986	Special Competency in Cardiac Pacing North American Society of Pace and Electrophysiology
1981	Diplomate American Board of Cardiovascular Disease
1978	Diplomate American Board of Internal Medicine
2009 – Present	Radiation Safety Officer

Curriculum Vitae

LICENSURE INFORMATION

1982- Present	State of Texas State Board License Number G4209
1980- Present	State of Florida State Board License Number 080940
1976	FLEX
1973	Educational Committee Foreign Medical Graduates Certification

SKILLS

Exercise stress testing
Holter monitoring
Echocardiography and doppler
Cardiac Catheterization and angiography
Intra-coronary thrombolytic therapy
Temporary and permanent pacemaker insertion
Endomyocardial biopsy
Pericardiocentesis
Swan-Ganz catheter insertion
Intra Aortic Balloon Counter pulsation
Coronary Interventions:
PTCA, Coronary Stents
Cardiopulmonary Support PTCA/stent
Balloon Aortic Valvuloplasty / TAVR
Peripheral Diagnostic Angiography
Peripheral Interventions:Arthrectomy, PTA, Stents
Angioplasty, Stents
Transesophageal Echocardiography
Endovascular Exclusion of Abdominal Aortic Aneurysm
Carotid Stenting
SPECT and Cardiac PET Interpretation
Cardiac Computer Tomography
Hemodialysis Access Interventions
Venous Interventions and Ablations

MEMBERSHIP IN SCIENTIFIC SOCIETIES

Fellow American College of Cardiology
Fellow American College of Chest Physicians
Fellow Society for Cardiac Angiography and Interventions 11/1993
Jefferson County Medical Society
American Heart Association - President 1985-1986
Texas Medical Association

Curriculum Vitae**COMMITTEE MEMBERSHIPS**

1/2014-1/2018	Chairman of Cardiology and Critical Care Baptist Hospital of Southeast Texas
1997 - 1999	Co - Medical Director Cardiac Catherization Laboratory Baptist Hospital of Southeast Texas
1997 - 1999	Medical Director Cardiovascular Program Baptist Hospital of Southeast Texas
1994 - 1995	Medical Director Cardiovascular Intensive Care Unit St. Elizabeth Hospital

CLINICAL RESEARCH

3/28/1998 - 2001	Principal Investigator Proctor & Gamble Protocol # 1997017 ALIVE Trial
1/2000 - 2001	Principal Investigator Bristol-Myers Squibb Protocol # CV137-072 Switch Trial
1/2000 - 2001	Principal Investigator Bristol-Myers Squibb Protocol # CV123-228 PRINCE Study
9/2000 - 2001	Principal Investigator Bristol-Myers Squibb Protocol # CV137-120 OCTAVE Study
1/2000 - 12/2001	Principal Investigator Parke-Davis Pfizer Protocol # 981-400-421 Sage Study-how lowering lipids effects myocardial ischemia in elderly
2/2000 - 4/2002	Principal Investigator G.E. Searls and Co. Protocol # IE3-99-02-035 Ephesus Study - Post MI study
2000 - 12/2001	Principal Investigator NitroMed Protocol # NDA # 20-727 A-HeFT Study - African American Heart Failure Trial

Curriculum VitaeCLINICAL RESEARCH

5/1/2002	Principal Investigator Pfizer Protocol # A3841012 Gemini Study - Lipitor/ Norvasc
8/2002 – 2005	Principal Investigator Aventis Protocol XRP4563B/4001 Rescue ACS Study – Acute Coronary Syndrome Study
12/2003 – 12/2006	Principal Investigator Otsuka Maryland Research Institute Protocol 156-03-236 Acute Decompensated – CHF Study
9/2006 – 9/2007	Principal Investigator Pfizer Protocol A3841046 HTN and Hyperlipidemia– Caduet
7/2004 – 12/2006	Principal Investigator Pfizer Protocol A5091043 Hypercholesterolemia and CV events– torceptrapib/atorvastatin
12/2005 – 9/2007	Principal Investigator AstraZeneca Protocol 4522US/0001 ACS– Rosuvastatin/Atorvastatin
8/2006 – 4/2009	Principal Investigator Amgen, Inc Protocol 20050222 Heart Failure and Anemia– Darbepoetin Alfa
10/2005 – 2007	Principal Investigator Lilly Protocol H7T-MC-TAAL ACS– Prasugrel and ASA vs. Clopidogrel and ASA
2/2006 – 6/2009	Principal Investigator Amgen, Inc. Protocol 20010184 Diabetes, CKD, and anemia– Darbepoetin Alfa

Curriculum Vitae

CLINICAL RESEARCH

6/2006 – 12/2006	Principal Investigator Palatin Technologies Protocol PT-141-2006-32 HTN safety for ED drug– PT-141
8/2006 – 6/2008	Principal Investigator Novartis Protocol CVAL489AUS62 Observational Study for BP– Diovan and Lotrel
2006 – 2010	Principal Investigator Johnson & Johnson Protocol 9039039 AFL301 Atrial Fibrillation– Rivaroxiban and Coumadin
12/2006 – 2012	Principal Investigator Pfizer Protocol A3191172 Osteoarthritis and Rheumatoid Arthritis– Celebrex, Naproxen and Aleve
2006 – 5/2009	Sub-Investigator Reliant Protocol OM8 Atrial Fibrillation– Omacor
2006 – 6/2009	Sub-Investigator Gilead Protocol DAR312 Resistant Hypertension– Darusentan and Guanfacine
3/2007 – 12/2008	Principal Investigator Merck Protocol 112-01 Hypercholesterolemia– Exetimibe and Atorvastatin
5/2008 – 01/2009	Principal Investigator Cogentus Protocol CG104 Reduce GI Events and Bleeding– Clopidogrel and CGT-2168
11/2008 – 6/2009	Principal Investigator Bristol Myers Squibb/Pfizer Protocol CV 185057 Deep Vein Thrombosis and Pulmonary Embolism– Apixiban

Curriculum VitaeCLINICAL RESEARCH

02/2009 – 2009	Principal Investigator Roche Protocol NC20971C Hypercholesterolemia-dalcetrapib
04/2010 – 8/2014	Principal Investigator Novartis Protocol CLCZ696B2314 Chronic heart failure and reduced LVEF. – enalapril – ACE /NEP Inhibitor
03/2010 – 1/2012	Principal Investigator Pozen Protocol PA32540-302 Incidence of Gastric Ulcers – ASA /omeprazole
07/2010 – 8/2014	Principal Investigator Ortho-McNeil Janssen RIVAROX-AFL-4001 ORBIT - Atrial Fibrillation Observational Registry
04/2011 – 1/2012	Sub-Investigator Novartis Protocol CSPV100AUS02 VIVID - Hypertension / Type 2 Diabetes– Aliskiren / Valsartan
04/2011 - Present	Principal Investigator Novartis Protocol CACZ885M2301 CANTOS - Post Myocardial Infarction / elevated hsCRP– canakinumab
11/2011 – Present	Sub Investigator Boston Scientific Multi-SENSE Device Trial
05/2012 - Present	Principal Investigator Amarin Protocol AMR -01-01-0019 Reduce-It Trial
08/2012 - Present	Principal Investigator Boehringer Ingleheim GLORIA-AF New Onset Atrial Fibrillation Registry
08/2012 – 12/2013	Principal Investigator Astra Zeneca D513L00013

Curriculum Vitae

CLINICAL RESEARCH

08/2012 – 12/2013	Principal Investigator Astra Zeneca Protocol D513L00013 Ethnicity Study- Stable CAD
08/2012 – 4/2013	Principal Investigator Takeda Protocol SYR-322-402 EXAMINE- Aldogliptin
08/2012 – 2/2015	Sub-Investigator DCRI / NIH Protocol 1U01HL086755.01A1 BRIDGE study
08/2013 - Present	Sub-Investigator Boston Scientific LSS of 4-SITE – Longitudinal Surveillance Study
11/2013 - 2014	Principal Investigator Novartis Protocol CLCZ696B2228 TITRATION Trial– enalapril – ACE /NEP Inhibitor
2/2014 - Present	Principal Investigator NHLBI CIRT Trial - Methotrexate
4/2014 - Present	Sub-Investigator Boston Scientific NAVIGATE X4
4/2014 – 8/2015	Sub-Investigator ARCA Biopharma GENETIC-AF
6/2014 – 3/2015	Principal Investigator Sanofi Multaq Chart Review – Atrial Fibrillation
7/2014 - Present	Principal Investigator Novartis Protocol CLCZ696D2301 PARAGON– enalapril – ACE /NEP Inhibitor

Curriculum VitaeCLINICAL RESEARCH

8/2014 - Present	Sub-Investigator Pfizer / BMS Protocol B0661025 / CB185-267 EMANATE
06/2013 - Present	Principal Investigator Ortho-McNeil Janssen RIVAROX-AFL-4002 ORBIT II - Atrial Fibrillation Observational Registry SATELLITE – Substudy 2015
06/2015 – Present	Principal Investigator AstraZeneca D513BC00001 THEMIS
08/2015 – Present	Principal Investigator Regeneron / DCRI PALM REGISTRY
08/2015 – Present	Principal Investigator Pfizer B1481022 SPIRE 1 – Hyperlipidemia
08/2015 – Present	Principal Investigator Pfizer B1481038 SPIRE 2 – Hyperlipidemia
01/2016 – Present	Principal Investigator Novartis CLCZ696BUS02 CHAMP-HF

PUBLICATIONS***Coronary Angioplasty in Emergency Treatment of Myocardial Infarction in a Community-Hospital Setting***

Sotolongo, R.P., Smith, M.L., and Margolis, W.S.

THIJ 17: pg 31-36, 1990

Coronary Angioplasty in the Treatment of Cardiogenic Shock in a Community Hospital

Presented at the 18th Annual Symposium of the Texas Heart Institute

September 28 - October 1, 1988

Curriculum Vitae

PUBLICATIONS

Left Atrial Motion in Total Electrical Alterans

Sotolongo, R.P. and Horton, J.
AHJ June 1981

Hypersensitivity Reaction to Sulfasalazine with Severe Hepatotoxicity

Sotolongo, R.P., Neefe, L., Rudzki, C. and Ishak, K.
Gastroenterology 1978

Serum Magnesium and Myocardial Diseases

Zonsein, J. and Sotolongo, R.P.
NEJM 297: 170, 1977

AWARDS

April 10, 2003

J.C. Crager Award, American Heart Association

BIOGRAPHY

Date of Birth	March 2, 1952
Place of Birth	Havana, Cuba
Citizenship	USA 1970
Marital Status	Married
Children	Three
Languages	English, Spanish